8-K: Servier to Acquire Day One Biopharmaceuticals for $2.5B

Servier Pharmaceuticals will acquire Day One Biopharmaceuticals for $21.50 per share in cash, valuing the company at approximately $2.5 billion.

Summary

• Servier Pharmaceuticals LLC, through its subsidiary Servier Detroit Inc., will acquire Day One Biopharmaceuticals, Inc. (DAWN) for $21.50 per share in cash.
• The total equity value of the transaction is approximately $2.5 billion.
• The offer price represents a premium of approximately 68% over Day One's closing price on March 5, 2026, and an 86% premium over its one-month volume-weighted average price (VWAP) as of the same date.
• The acquisition will be structured as a cash tender offer for all outstanding shares, followed by a second-step merger under Section 251(h) of the Delaware General Corporation Law, which does not require a stockholder meeting.
• Consummation of the tender offer is subject to customary closing conditions, including a majority of Day One's outstanding shares being tendered and U.S. antitrust clearance.
• All outstanding unvested stock options and restricted stock units will become fully vested immediately prior to the merger's effective time and converted into cash based on the offer price.
• Day One's Board of Directors has unanimously recommended that shareholders accept the offer and tender their shares.
• Servier S.A.S. (Guarantor) has guaranteed the full and timely payment of all amounts payable by Parent or Merger Sub under the Merger Agreement.
• The transaction is not subject to a financing condition, with Servier expecting to fund it through existing cash and investments.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development for Day One shareholders, given the substantial premium offered and the strategic alignment with Servier, which provides a clear path to liquidity and continued development of Day One's pipeline.

Positives

• Shareholders receive a significant premium of approximately 68% over the closing price and 86% over the one-month VWAP as of March 5, 2026.
• The acquisition strengthens Servier's position in rare oncology and expands its pipeline with programs ranging from early stage to Phase 3.
• Day One's unvested stock options and restricted stock units will become fully vested and converted to cash, benefiting equity award holders.
• The transaction is not subject to a financing condition, reducing uncertainty regarding funding.

Negatives

• No explicit negatives are mentioned in the filing regarding the company's performance or outlook, as this is an acquisition announcement.

Risks

• Uncertainties exist regarding the timing of the tender offer and subsequent merger.
• There is a risk that not enough Day One stockholders will tender their shares in the offer.
• Competing offers or acquisition proposals could emerge, potentially disrupting the current agreement.
• Various conditions to the consummation of the merger and the offer may not be satisfied or waived, including regulatory approvals.
• The announcement and pendency of the transactions may make it more difficult for Day One to establish or maintain relationships with employees, suppliers, and other business partners.
• Stockholder litigation in connection with the offer or merger may result in significant costs of defense, indemnification, and liability.
• Day One operates in a very competitive and rapidly changing environment, which could impact future results if the transaction does not close.

Future Outlook

The acquisition is expected to close in the second quarter of 2026, subject to customary closing conditions. Servier anticipates that this acquisition will reinforce its position in oncology targeted therapies and expand its pipeline, particularly in rare cancers and neurological diseases. Day One believes joining Servier will extend the reach of its science and lead program in pediatric low-grade glioma.

Management Comments

• Olivier Laureau, President of Servier: "This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier's position in rare oncology... It reflects our long-term commitment to investing in science that can make a meaningful difference for patients. This announcement is fully aligned with our 2030 ambition, and we believe that combining our expertise will accelerate innovation for people living with a rare cancer."
• Jeremy Bender, Ph.D., CEO of Day One: "Servier's successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One's mission to bring medicines to patients of all ages with life threatening diseases... Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low-grade glioma. Importantly, Servier's dedication to the rare disease community preserves the patient-first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve."

Industry Context

StockSavvy.ai notes that this acquisition positions Servier as a leader in pediatric low-grade glioma, a rare oncology indication, and significantly expands its oncology pipeline. This move aligns with broader industry trends of pharmaceutical companies seeking to acquire specialized biotech firms to bolster their portfolios in high-growth therapeutic areas, particularly rare diseases and targeted therapies where unmet medical needs are significant. For Day One, the acquisition by an established international pharmaceutical group like Servier provides the resources and global capabilities to accelerate the development and commercialization of its products, such as OJEMDA, Emi-Le, and DAY301.

Comparison to Industry Standards

• The offer price of $21.50 per share represents a substantial premium of 68% over Day One's closing price and 86% over its one-month VWAP, which is generally considered a strong premium in biotech acquisitions, often reflecting the strategic value of the target company's pipeline and market position.
• The total equity value of $2.5 billion for Day One, a commercial-stage biopharmaceutical company focused on pediatric cancer, is a notable valuation within the rare oncology space, indicating strong confidence in its lead programs like OJEMDA (tovorafenib) for pediatric low-grade glioma.

Management Changes

Corporate Governance

Legal Proceedings

• The forward-looking statements section mentions the risk that stockholder litigation in connection with the Offer or the Merger may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Will receive a significant cash premium for their shares, representing a substantial return on investment.
• Employees: Unvested equity awards will fully vest, and employees will receive comparable base salary, target cash incentive opportunity, and other benefits for one year post-merger, with service recognition for benefit plans. However, there is a risk of disruption and difficulty maintaining relationships with employees due to the transaction.
• Customers and Suppliers: There is a risk that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with suppliers and other business partners.
• Management: Current directors and officers will resign, with new management from Merger Sub taking over. Existing indemnification rights are preserved.

Next Steps

• Merger Sub will commence a cash tender offer no later than 15 business days after March 6, 2026.
• Day One will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• Following the tender offer, Merger Sub will merge with Day One, with Day One surviving as a wholly owned subsidiary of Servier Pharmaceuticals LLC.
• Day One's common stock and other securities will be delisted from Nasdaq and de-registered under the Exchange Act as promptly as practicable following the Effective Time.

Key Dates

Recommendation

For existing shareholders of Day One Biopharmaceuticals, the recommendation is a strong buy (to tender shares) given the substantial premium offered by Servier. The $21.50 per share cash offer represents a 68% premium over the previous day's closing price and an 86% premium over the one-month VWAP, providing a clear and attractive liquidity event. The transaction is not subject to a financing condition, reducing execution risk. While there are customary closing conditions and risks of competing offers or litigation, the board's unanimous recommendation and the high premium make tendering shares the most financially advantageous path for current holders. For new investors, the opportunity for significant upside is limited given the announced acquisition price, making it less attractive for new positions unless there's an expectation of a higher competing bid.

Keywords

Acquisition, Merger, Tender Offer, Biopharmaceuticals, Oncology, Rare Cancers, Pediatric Low-Grade Glioma, Day One Biopharmaceuticals, Servier Pharmaceuticals, DAWN, Healthcare, Biotech